Literature DB >> 19242932

Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line.

Joanne Keenan1, Lisa Murphy, Michael Henry, Paula Meleady, Martin Clynes.   

Abstract

Alterations in protein expression associated with adriamycin resistance in a panel of variants derived from the poorly differentiated squamous cell lung carcinoma DLKP were investigated using 2-D DIGE. Of the 80 proteins identified as being differentially expressed, 32 correlated to adriamycin resistance. Twenty-four proteins showed positive correlations with drug resistance, 11 correlated directly with increase in the resistance (including NDPK, RPA2, CCT2, HSP70 and Annexin A1) while 13 proteins (including HNRP K and H1, aldehyde dehydrogenase (ALDH), stomatin and CCT3) increased to a similar level in all drug-resistant variants. Fewer proteins showed an inverse correlation with resistance; two (protein disulphide isomerase (PDI) and HSP70 variant 1) displayed a similar decrease in all variants and six (including prohibitin (PHB) and EIF5A) correlated inversely with resistance. Three proteins (EEF1D, Actin G1 and Annexin 1) correlated with the invasive status of these variants. Some expected targets of adriamycin action showed correlation with resistance including RPA2 (critical for DNA damage repair), while others proteins involved in protection from ROS production (such as GST, peroxiredoxins and thioredoxins) did not. The proteomic analysis revealed a large number of changes in protein expression that may contribute to a more apoptosis-resistant state. Many of these changes could provide novel targets for overcoming resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19242932     DOI: 10.1002/pmic.200800633

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  21 in total

Review 1.  The grand challenge to decipher the cancer proteome.

Authors:  Samir Hanash; Ayumu Taguchi
Journal:  Nat Rev Cancer       Date:  2010-09       Impact factor: 60.716

2.  Nonparametric Bayesian evaluation of differential protein quantification.

Authors:  Oliver Serang; A Ertugrul Cansizoglu; Lukas Käll; Hanno Steen; Judith A Steen
Journal:  J Proteome Res       Date:  2013-09-11       Impact factor: 4.466

3.  Stomatin-like protein 2 expression is associated with clinical survival in patients with cervical cancer.

Authors:  Binmei Xiao; Zhiyi Xie; Lan Guo; Jianchi Wu; Hongwen Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids.

Authors:  Marco Mrusek; Ean-Jeong Seo; Henry Johannes Greten; Michael Simon; Thomas Efferth
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

5.  Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.

Authors:  Manimalha Balasubramani; Chitose Nakao; Guy T Uechi; John Cardamone; Kathy Kamath; Kristen L Leslie; Raghavan Balachandran; Leslie Wilson; Billy W Day; Mary Ann Jordan
Journal:  Mutat Res       Date:  2010-09-09       Impact factor: 2.433

6.  Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer.

Authors:  Yiqing Qu; Yie Yang; Baoyi Liu; Wei Xiao
Journal:  Med Oncol       Date:  2009-12-10       Impact factor: 3.064

7.  Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.

Authors:  Kunpeng Liu; Yuan Ren; Lijuan Pang; Yan Qi; Wei Jia; Lin Tao; Zhengyan Hu; Jin Zhao; Haijun Zhang; Li Li; Haifeng Yue; Juan Han; Weihua Liang; Jianming Hu; Hong Zou; Xianglin Yuan; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

8.  Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2.

Authors:  Laszlo Gyenis; James S Duncan; Jacob P Turowec; Maria Bretner; David W Litchfield
Journal:  J Proteome Res       Date:  2011-10-13       Impact factor: 4.466

9.  The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma.

Authors:  Timothy B Lautz; Chunfa Jie; Sandra Clark; Jessica A Naiditch; Nadereh Jafari; Yi-Yong Qiu; Xin Zheng; Fei Chu; Mary Beth Madonna
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

10.  Cancer cell response to anthracyclines effects: mysteries of the hidden proteins associated with these drugs.

Authors:  Jirina Tyleckova; Rita Hrabakova; Katerina Mairychova; Petr Halada; Lenka Radova; Petr Dzubak; Marian Hajduch; Suresh J Gadher; Hana Kovarova
Journal:  Int J Mol Sci       Date:  2012-11-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.